Apollomics, Inc. (APLMW) Stock Price & Analysis
Apollomics, Inc. (APLMW) — price $0.0105 (-21.64%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Apollomics, Inc. · APLMW
Apollomics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of oncology therapies. The company addresses unmet medical needs in the oncology space.
Price as of Oct 2, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0105 | |
| Change on the day | -21.64% | |
| 52-week range | $0.0115 – $0.026 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Apollomics (APLMW): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the APLMW film — every key number, told as a short cinematic story
~2 min · open the film
What is Apollomics (APLMW), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Apollomics, Inc. (APLMW) is the company analyzed here. It employs 14 people and is led by Hung-Wen Chen. In Q2 FY2025 it reported revenue of $9M and net income of -$13M.
What do the latest results show for Apollomics (APLMW)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of $9M.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | $9M | -$13M | -$11.37 (diluted) |
| Q2 FY2024 | $2M | -$35M | -$38.00 (diluted) |
What are the financial strengths and risks for Apollomics (APLMW)?
Short answer · as of
Trailing ratios: ROE 288.4% · current ratio 0.96 · earnings yield -109.0% · free-cash-flow yield -19.8%.
What should you watch next at Apollomics (APLMW)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -122.00 · 0 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No Altman Z or Piotroski screen is held for this filer.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $0.00
- EPS estimate
- $-122.00
Measured against a quoted price of $0.0105 (as of Oct 2, 2026).
Apollomics Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the APLMW research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What do analysts say about APLMW stock?
Analyst coverage of Apollomics, Inc. (APLMW) is limited due to its size and stage of development. However, the consensus view is that the company's success hinges on the outcome of its clinical trials and regulatory approvals.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 7 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.0105 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:54:35.889Z. | |
px.change | Change on the day | -21.64% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$0.0029 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 100 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2025 | $9M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2025 | -$13M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 2 quarters through Q2 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 7 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.0115 – $0.026 | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
id.employees | Employees | 14 | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
id.ceo | Chief executive | Hung-Wen Chen | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 288.4% · current ratio 0.96 · earnings yield -109.0% · free-cash-flow yield -19.8% | UNRECORDED | Stored key metrics — Captured 2026-09-29 · Expired observation | |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $0.00 · EPS -122.00 · 0 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $0.00 | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-122.00 | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.